company background image
OBSV

ObsEvaNasdaqGS:OBSV Stock Report

Market Cap

US$150.3m

7D

-9.8%

1Y

-6.0%

Updated

04 Dec, 2021

Data

Company Financials +
OBSV fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

OBSV Stock Overview

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy.

Price History & Performance

Summary of all time highs, changes and price drops for ObsEva
Historical stock prices
Current Share PriceUS$2.02
52 Week HighUS$5.55
52 Week LowUS$1.93
Beta0.64
1 Month Change-19.52%
3 Month Change-36.08%
1 Year Change-6.05%
3 Year Change-86.13%
5 Year Changen/a
Change since IPO-82.66%

Recent News & Updates

Shareholder Returns

OBSVUS BiotechsUS Market
7D-9.8%-4.1%-2.7%
1Y-6.0%-1.4%16.6%

Return vs Industry: OBSV underperformed the US Biotechs industry which returned -1.4% over the past year.

Return vs Market: OBSV underperformed the US Market which returned 16.6% over the past year.

Price Volatility

Is OBSV's price volatile compared to industry and market?
OBSV volatility
OBSV Average Weekly Movement6.8%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: OBSV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: OBSV's weekly volatility has decreased from 13% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201243Brian O'Callaghanhttps://www.obseva.com

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization.

ObsEva Fundamentals Summary

How do ObsEva's earnings and revenue compare to its market cap?
OBSV fundamental statistics
Market CapUS$150.34m
Earnings (TTM)-US$56.88m
Revenue (TTM)US$25.00m

6.0x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OBSV income statement (TTM)
RevenueUS$25.00m
Cost of RevenueUS$0
Gross ProfitUS$25.00m
ExpensesUS$81.88m
Earnings-US$56.88m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.76
Gross Margin100.00%
Net Profit Margin-227.52%
Debt/Equity Ratio58.0%

How did OBSV perform over the long term?

See historical performance and comparison

Valuation

Is ObsEva undervalued compared to its fair value and its price relative to the market?

3.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OBSV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OBSV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OBSV is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: OBSV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OBSV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OBSV is overvalued based on its PB Ratio (3.4x) compared to the US Biotechs industry average (2.6x).


Future Growth

How is ObsEva forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-34.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OBSV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OBSV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OBSV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OBSV's revenue is expected to decline over the next 3 years (-98.1% per year).

High Growth Revenue: OBSV's revenue is forecast to decline over the next 3 years (-98.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OBSV's Return on Equity is forecast to be high in 3 years time


Past Performance

How has ObsEva performed over the past 5 years?

-13.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OBSV is currently unprofitable.

Growing Profit Margin: OBSV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OBSV is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.

Accelerating Growth: Unable to compare OBSV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OBSV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: OBSV has a negative Return on Equity (-128.78%), as it is currently unprofitable.


Financial Health

How is ObsEva's financial position?


Financial Position Analysis

Short Term Liabilities: OBSV's short term assets ($72.1M) exceed its short term liabilities ($18.8M).

Long Term Liabilities: OBSV's short term assets ($72.1M) exceed its long term liabilities ($34.7M).


Debt to Equity History and Analysis

Debt Level: OBSV has more cash than its total debt.

Reducing Debt: Insufficient data to determine if OBSV's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OBSV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OBSV has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17% each year


Dividend

What is ObsEva current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OBSV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OBSV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OBSV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OBSV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OBSV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Brian O'Callaghan (52 yo)

1

Tenure

US$4,290,000

Compensation

Mr. Brian O'Callaghan has been Director at Bolt Biotherapeutics, Inc. since November 2021. Mr. O'Callaghan serves as Chief Executive Officer of ObsEva SA since December 1, 2020 and serves as its Director s...


CEO Compensation Analysis

Compensation vs Market: Brian's total compensation ($USD4.29M) is above average for companies of similar size in the US market ($USD1.15M).

Compensation vs Earnings: Insufficient data to compare Brian's compensation with company performance.


Leadership Team

Experienced Management: OBSV's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: OBSV's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.7%.


Top Shareholders

Company Information

ObsEva SA's employee growth, exchange listings and data sources


Key Information

  • Name: ObsEva SA
  • Ticker: OBSV
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$150.344m
  • Shares outstanding: 74.43m
  • Website: https://www.obseva.com

Number of Employees


Location

  • ObsEva SA
  • Chemin des Aulx, 12
  • Plan-les-Ouates
  • Geneva
  • Geneva
  • 1228
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/04 00:14
End of Day Share Price2021/12/03 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.